 | PepsRadar THE WEEKLY · NOV 2 – NOV 15 |
Peptide claims vs. the real studies. Here is what changed this week. |
 Research field guide Semaglutide not working? Why some people lose less, and what the trials showMost people on semaglutide lose meaningful weight, but not everyone does. How many respond in the trials, why people with type 2 diabetes tend to lose less, what a new gene study found, and what the evidence says about switching or stopping. Read the guide → |
|
 For members Member deals & codes → This week's seller codes and announced sales, checked every Sunday and collected in your free members area. |
|
|
|
|
|
|
|
|
|
|
|
Clinical trial updates From our weekly ClinicalTrials.gov checks. A registration is a plan, not a result. |
Status changeUBT251Phase 3active, not recruiting |
New studySemaglutidePhase 3recruiting |
New studySemaglutidePhase 2 / Phase 3not yet recruiting |
New studySemaglutidePhase 3not yet recruiting |
New studySemaglutidePhase 3completed |
New studySemaglutidePhase 2 / Phase 3recruiting |
| See all 12 trial updates in the tracker → |
|
November 9, 2026 Dulaglutide, Exenatide, Liraglutide and 4 more: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. |
|
|
Know someone who'd want this? Forward this email, or send them to pepsradar.com/newsletter to sign up free with just an email address. |
For research and education only. PepsRadar summarizes published research and public records; it is not medical advice, has not been reviewed by a medical professional, and never gives dosing instructions. The member deals link opens PepsRadar's members area, where seller links may be affiliate links and PepsRadar may earn a commission. This email names no sellers or products. |
Got this from a friend? Get the PepsRadar Weekly free every Monday: sign up with just your email. |